Jennifer L. Atlas, MD

Drs Babakoohi and Atlas share clinical pearls for community oncologists on treating basal cell carcinoma.

A look at how common metastatic basal cell carcinoma is in clinical practice and when to consider frontline immunotherapy.

Experts review the safety and toxicity data of anti-PD-1 antibody agent cemiplimab for basal cell carcinoma treatment.

Jennifer Atlas, MD, presents the case of a 66-year-old woman with locally advanced basal cell carcinoma not responding to frontline treatment.

Shahab Babakoohi, MD, describes his monitoring strategies for patients with basal cell carcinoma.

Dr Jennifer Atlas leads a conversation on systemic therapy options in basal cell carcinoma with a review of clinical trial data.

Experts review the currently available treatment options for locally advanced basal cell carcinoma.

Dr. Shahab Babakoohi explains when to refer a patient with basal cell carcinoma from a dermatology practice to a medical oncologist.

Jennifer Atlas, MD, presents the clinical scenario of a man with locally advanced basal cell carcinoma.

Shahab Babakoohi, MD, describes the incidence patterns, options for testing and diagnosis, and risk stratification for basal cell carcinoma.

Jennifer L. Atlas, MD, discusses the promise of cemiplimab in the treatment of patients with locally advanced cutaneous squamous cell carcinoma.

Jennifer L. Atlas, MD, discusses the ​current cutaneous squamous cell carcinoma treatment paradigm.

Jennifer L. Atlas, MD, discusses the rationale for using cemiplimab-rwlc as a first intervention for patients with locally advanced cutaneous squamous cell carcinoma.